Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae.

Rivera-Robles MJ, Medina-Vel?zquez J, Asencio-Torres GM, Gonz?lez-Crespo S, Rymond BC, Rodr?guez-Medina J, Dharmawardhane S. Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae. Small GTPases. 2020 11; 11(6):430-440.

View in: PubMed

subject areas

Antineoplastic Agents
cdc42 GTP-Binding Protein
Cell Polarity
Cell Proliferation
Dose-Response Relationship, Drug
Molecular Structure
Saccharomycetales

authors with profiles

José R. Rodríguez-Medina
Suranganie Dharmawardhane

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support